Program Type
Disease
Project Status

Displaying 1 - 25 of 195

TRUST: Gene and Protein Expression Biomarkers for Frequent Gout Flaring
This project’s objective is to build a predictive multi-omics model for gout flares....
RECOVER-TLC Will Advance Long COVID Research
RECOVER-TLC unites the scientific and patient community in finding new approaches to address Long COVID. This FNIH program is led by NIAID....
The Sound Health Music Science Fellowships Program
Music is more than just sound—it’s a powerful tool that can heal, restore, and transform. The Sound Health Music Science Fellowships wil...
The Kovler Prize for Trust in Life Science Journalism
In its inaugural year, the Kovler Prize for Trust in Life Science Journalism honors an individual who has significantly increased the public...
What AMP® PDRD Partners Are Saying
Aligning Science Across Parkinson’s “Aligning Science Across Parkinson’s (ASAP) is excited to be part of AMP PDRD and work towards ...
AMP Parkinson’s Disease and Related Disorders
AMP Parkinson’s Disease and Related Disorders (AMP PDRD) builds on the infrastructure established during AMP Parkinson’s Disease (AMP PD...
What MMyeRisk Partners Are Saying
AbbVie “At AbbVie, we are committed to improving outcomes for patients with multiple myeloma (MM) and recognize that addressing the tou...
Joint FDA/FNIH Workshop for Digital Measures
FNIH conducted a joint FDA/FNIH workshop for Digital Measures that brought together industry leaders, regulatory bodies, researchers, and pa...
Molecular Characterization and Diagnostic Biomarkers of Sjögren’s Disease
Better define and understand disease heterogeneity and identify diagnostic biomarkers for patient stratification....
MASHtrack: Tracking Liver Fibrosis and Outcomes Through Non-Invasive Prognostic Biomarkers in Patients with Metabolic Dysfunction-Associated Steatohepatitis
MASHtrack is a prognostic study seeking to investigate whether the diagnostic biomarkers identified in the FNIH’s Non-Invasive Biomarkers ...
What AMP® ALS Partners Are Saying
ALS Association “It will take all of us working together to make ALS a livable disease and ultimately find a cure. That is why we are p...
AMP Amyotrophic Lateral Sclerosis
The Accelerating Medicines Partnership® (AMP®) Amyotrophic Lateral Sclerosis (AMP ALS) is accelerating therapeutic and biomarker developme...
What iRelate Partners and Supporters Are Saying
CellSight Technologies, Inc. "CellSight is proud to support and excited to participate in the FNIH iRelate project, which seeks to unders...
AMP Amyotrophic Lateral Sclerosis (ALS) Design Phase
Team Science Day 2024
MMyeRisk: Defining Tumor and Immune Markers to Stratify Patients at Risk of Developing Multiple Myeloma from MGUS and Smoldering Myeloma
AMP Cell-Based Therapy Consortium
AMP Symposium
February 5-6, 2024 – North Bethesda, MD The Accelerating Medicines Partnership® (AMP®) Program was launched in February 2014 to bring t...
AMP Systems Biology of Inflammation
Cognitive Aging Summit IV
Biomarkers Consortium – Biomarkers for Risk Stratification and Detection of Early-Onset Preeclampsia
iRelate: Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
Convening Experts in Oncology to Address Children’s Health (COACH)
Targeted Gene Delivery for Sickle Cell Disease
Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)

Diseases

Partner With Us